发明名称 APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
摘要 Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
申请公布号 US2016206611(A1) 申请公布日期 2016.07.21
申请号 US201614994824 申请日期 2016.01.13
申请人 AbbVie Inc. 发明人 Wang Le;Doherty George;Wang Xilu;Tao Zhi-Fu;Bruncko Milan;Kunzer Aaron R.;Wendt Michael D.;Song Xiaohong;Frey Robin;Hansen Todd M.;Sullivan Gerard M.;Judd Andrew;Souers Andrew
分类号 A61K31/4725;A61K31/5377;C07D417/14 主分类号 A61K31/4725
代理机构 代理人
主权项 1. A compound having Formula (I)or a therapeutically acceptable salt thereof, or a therapeutically acceptable salt thereof, wherein X is heteroaryl; wherein the heteroaryl represented by X is optionally substituted with one, two, three, or four R4; Y1 is phenylene, or C5-6 heteroarylene; optionally fused to one or two rings selected from the group consisting of C3-8 cycloalkane, C3-8 cycloalkene, benzene, C5-6 heteroarene, C3-8 heterocycloalkane, and C3-8 heterocycloalkene; wherein Y1 is optionally substituted with one, two, three, or four substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, CO(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, CO(O)H, C(O)H, OH, CN, N3, NO2, F, Cl, Br and I; L1 is selected from the group consisting of (CR6R7)q, (CR6R7)s—O—(CR6R7)r, (CR6R7)s—C(O)—(CR6R7)r, (CR6R7)s—S—(CR6R7)r, (CR6R7)s—S(O)2—(CR6R7)r, (CR6R7)s—NR6AC(O)—(CR6R7)r, (CR6R7)s—C(O)NR6A—(CR6R7)r, (CR6R7)x—NR6A—(CR6R7)r, (CR6R7)s—S(O)2NR6A—(CR6R7)r, and (CR6R7)s—NR6AS(O)2—(CR6R7)r; and Y2 is selected from the group consisting of C3-11 branched chain alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, phenyl, and C3-7 heterocyclyl; wherein the C3-7 cycloalkyl, C4-7 cycloalkenyl, phenyl, and C3-7 heterocyclyl are optionally fused to one or two rings selected from the group consisting of C3-8 cycloalkane, C3-8 cycloalkene, benzene, C5-6 heteroarene, C3-8 heterocycloalkane, and C3-8 heterocycloalkene; wherein Y2 is optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, N(R8)2, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, CO(O)H, C(O)H, OH, CN, N3, NO2, F, Cl, Br and I; or L1 is a bond; and Y2 is selected from the group consisting of C3-7 cycloalkyl, C4-7 cycloalkenyl, phenyl, and C3-7 heterocyclyl; wherein the C3-7 cycloalkyl, C4-7 cycloalkenyl, phenyl, and C3-7 heterocyclyl represented by Y2 are optionally fused to one or two rings selected from the group consisting of C3-8 cycloalkane, C3-8 cycloalkene, benzene, C5-6 heteroarene, C3-8 heterocycloalkane, and C3-8 heterocycloalkene; wherein each Y2 and each ring fused to Y2 are optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, N(R8)2, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, CO(O)H, C(O)H, OH, CN, N3, NO2, F, Cl, Br and I; Z1 is selected from the group consisting of C(O)OR9, C(O)NR10R11, C(O)R11, NR10C(O)R11, NR10C(O)NR10R11, OC(O)NR10R11, NR10C(O)OR9, C(═NOR10)NR10R11, NR10C(═NCN)NR10R11, NR10S(O)2NR10R11, S(O)2R9, S(O)2NR10R11, N(R10)S(O)2R11, NR10C(═NR11)NR10R11, C(═S)NR10R11, C(═NR10)NR10R1, halogen, NO2, and CN; or Z1 is selected from the group consisting of R1, at each occurrence, is independently selected from the group consisting of halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl; R2, at each occurrence, is independently selected from the group consisting of deuterium, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl; two R2 that are attached to the same carbon atom, together with said carbon atom, optionally form a ring selected from the group consisting of heterocycloalkyl, heterocycloalkenyl, cycloalkyl, and cycloalkenyl; R3, at each occurrence, is independently selected from the group consisting of halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl; R4, at each occurrence, is independently selected from the group consisting of NR12R13, OR12, CN, NO2, halogen, C(O)OR12, C(O)NR12R13, NR12C(O)R13, NR12S(O)2R14, NR12S(O)R14, S(O)2R14, S(O)R14 and R14; R5, at each occurrence, is independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; R6A is independently selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 6 alkynyl, and C1-6 haloalkyl; R6 and R7, at each occurrence, are each independently selected from the group consisting of hydrogen, R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, CO(O)H, C(O)H, OH, CN, N3, NO2, F, Cl, Br and I; or R8, at each occurence, is independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the R8 C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl are optionally substituted with one, two, three, four, five, or six substituents independently selected from the group consisting of R16, OR16, SR16, S(O)R16, SO2R16, C(O)R16, CO(O)R16, OC(O)R16, OC(O)OR16, NH2, NHR16, N(R15)2, NHC(O)R16, NR16C(O)R16, NHS(O)2R16, NR16S(O)2R16, NHC(O)OR16, NR16C(O)OR16, NHC(O)NH2, NHC(O)NHR16, NHC(O)N(R16)2, NR16C(O)NHR16, NR15C(O)N(R16)2, C(O)NH2, C(O)NHR16, C(O)N(R16)2, C(O)NHOH, C(O)NHOR16, C(O)NHSO2R16, C(O)NR16SO2R16, SO2NH2, SO2NHR16, SO2N(R16)2, CO(O)H, C(O)H, OH, CN, N3, NO2, F, Cl, Br and I; wherein the R8 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl are optionally substituted with one, two, or three substituents independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, NH2, C(O)NH2, SO2NH2, C(O)H, (O), OH, CN, NO2, OCF3, OCF2CF3, F, Cl, Br and I; R9 is selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, cycloalkyl, phenyl and (CH2)1-4 phenyl; and R10 and R11, at each occurrence, are each independently selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 haloalkyl, phenyl and (CH2)1-4-phenyl; or R10 and R11, or R10 and R9, together with the atom to which each is attached are combined to form a heterocyclyl; Rk, at each occurrence, is independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 heterocycloalkyl, C3-7 cycloalkyl and C1-6 haloalkyl; wherein the Rk C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are optionally substituted with aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; R12 and R13, at each occurrence, are each independently selected from the group consisting of hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl and (CH2)1-4 phenyl; R14, at each occurrence, is independently selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl and C1-4 haloalkyl; R12 and R13, or R12 and R14, at each occurrence, together with the atom to which each is attached, are optionally combined to form a heterocyclyl; R15, at each occurrence, is independently selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the R15 C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, and C1-4 hydroxyalkyl are optionally substituted with one, two, or three substituents independently selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl, NH2, C(O)NH2, SO2NH2, C(O)H, C(O)OH, (O), OH, CN, NO2, OCF3, OCF2CF3, F, Cl, Br and I; R16, at each occurrence, is independently selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the R16 C1-4 alkyl, C2-4alkenyl, C2-4 alkynyl, C1-4 haloalkyl, and C1-4 hydroxyalkyl are optionally substituted with one substituent independently selected from the group consisting of OCH3, OCH2CH2OCH3, and OCH2CH2NHCH3; q is 1, 2, or 3; s is 0, 1, 2, or 3; r is 0, 1, 2, or 3; wherein the sum of s and r is 0, 1, or 2; m is 0, 1, 2, or 3; n is 0, 1, 2, 3, 4, 5, or 6; and p is 0, 1, or 2.
地址 North Chicago IL US